Sunnyside, a US-based Alcohol Use Disorder (AUD) treatment and prevention company, announced on Thursday the launch of two new programs that pair semaglutide, a GLP-1 medication, with naltrexone, a medication FDA-approved for alcohol dependence since 1994, as an innovative new option for adults who want to drink less or quit.

Both programs pair medication with Sunnyside's support program, which combines app-based tools and AI-driven personalisation with a layered human support system integrating peer connection, coaches, care coordinators, and licensed clinicians. The company says that insurance is not required.

Sunnyside Med says that its program is designed for prevention and early intervention, with medication prescribed as a first-line treatment, rather than a last resort.

Sunnyside Med's GLP-1 + Naltrexone Microdose Program costs USD199 a month, and the GLP-1 + Naltrexone Full Dose Program costs USD299 a month, plus a one-time USD50 intake fee, with specific BMI requirements for each program. Medication is shipped as an 84-day supply, and members check in with a provider before each refill shipment. Sunnyside Med's naltrexone-only program is still available at USD99 a month. Both new programs are available now, in all 50 states and Washington, D.C.

Semaglutide is not FDA-approved to treat alcohol use disorder.